CommercialCoverageMedium impact
Ycanth (cantharidin)
Blue Cross & Blue Shield of Mississippi·MS · Dermatology, Pediatrics, Family Medicine·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has established that Ycanth (cantharidin) for treating molluscum contagiosum is considered not medically necessary as covered alternatives exist. All services related to delivery and administration will be denied without prior authorization approval through BCBSMS PA review process.
Action Required
Immediately: Billing team must flag HCPCS code J7354 (Cantharidin for topical administration) as requiring prior authorization through BCBSMS PA review process before treatment. Update billing system to prevent claims submission without PA approval. Providers should consider covered alternatives for molluscum contagiosum treatment. Claims submitted without prior authorization will be denied as not medically necessary.